NASDAQ$NAMS
NewAmsterdam Pharma Company NV · Q2 2025 earnings
Q2 2025 earnings · · Before market open · Investor relations
Briefing
NewAmsterdam Pharma reported Q2 2025 revenue of $19.1 million and a net loss of $17.4 million.
NewAmsterdam Pharma Company N.V. reported revenue of $19.1 million for the three months ended June 30, 2025, primarily from its Menarini license agreement. The company recorded a net loss of $17.4 million and an operating loss of $35.6 million, with R&D expenses declining to $27.5 million. Cash, cash equivalents and marketable securities totaled $783.3 million at quarter end.
- Revenue increased to $19.1 million driven by recognition of $16.1 million in Menarini development cost contributions.
- Net loss narrowed to $17.4 million from $39.0 million in Q2 2024 due to lower R&D spend and foreign exchange gains.
- Cash position remained strong at $563.9 million plus $219.5 million in marketable securities.
- Positive Alzheimer's biomarker data from BROADWAY trial announced post-quarter end on July 30, 2025.
Headline financials
Revenue & EPS history
NewAmsterdam Pharma · Revenue · Quarterly
$19.1M
Forward guidance
Company continues to advance obicetrapib development and prepare for potential commercialization.
Tailwinds
- Strong cash position supports ongoing clinical and commercial activities.
- Positive AD biomarker data from BROADWAY trial announced in July 2025.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 17 quarterly earnings reports
+1.2%
Avg return
Earnings day
+3.0%
Avg return
5 days after
-0.6%
Avg return
30 days after
61%
11 / 18 earnings
Positive
+18.2%
Q3 2024
Best reaction
-9.6%
Q1 2024
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q2 2024 | — | — | — | |
| Q2 2025 | +8.7% | — | — | |
| Q1 2026 | +1.2% | +25.4% | +1.5% | |
| Q4 2025 | -3.0% | +2.6% | -17.9% | |
| Q3 2025 | +4.3% | +6.7% | -3.5% | |
| Q1 2025 | +1.2% | -8.3% | -3.2% | |
| Q4 2024 | +10.2% | +13.4% | +21.7% | |
| Q3 2024 | +18.2% | +28.4% | -4.2% | |
| Q1 2024 | -9.6% | -12.1% | -7.8% | |
| Q2 2023 | -5.7% | -4.9% | -2.4% | |
| Q4 2023 | -5.7% | -4.9% | -2.4% | |
| Q1 2023 | +0.3% | +2.0% | -0.9% | |
| Q4 2022 | +2.1% | +1.7% | +7.4% | |
| Q3 2022 | -0.1% | +0.1% | +0.8% | |
| Q2 2022 | +0.1% | +0.1% | +0.4% | |
| Q1 2022 | +0.0% | +0.1% | +0.3% | |
| Q3 2021 | -0.3% | +0.2% | -0.1% | |
| Q2 2021 | +0.2% | +0.2% | -1.2% | |
| Q1 2021 | +0.1% | +0.2% | +1.0% | |
| Q4 2020 | — | — | — | |
| Q3 2020 | — | — | — | |
| Q2 2020 | — | — | — | |
| Q1 2020 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro